DUOS TECHNOLOGIES GROUP, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DUOS TECHNOLOGIES GROUP, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.28M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.47M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.26M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.64M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.05M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $3.88M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $6.10M | Apr 2, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.28M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.47M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.26M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.64M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.05M | Mar 31, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.88M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $3.20M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.76M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $1.80M | Apr 1, 2016 |
| FY2014 | Dec 31, 2013 | $74.8K | Apr 17, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.88M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $469.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.75M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $235.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.48M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.20M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $1.59M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.37M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.84M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.86M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.01M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.75M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.47M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.58M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($5.15M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($2.56M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.98M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.45M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.87M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.46M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.63M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.41M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.57M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($3.44M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($1.74M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $846.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.53M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.65M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.52M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $102.2K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.48M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $488.7K | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $310.1K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $272.0K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.75M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.49M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.87M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.58M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.23M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.02M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($345.3K) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($3.56M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($1.84M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $496.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $344.9K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $545.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $279.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $206.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $212.4K | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $41.7K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $35.3K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.41M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $34.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $12.84M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.09M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.48M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.41M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.53M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.49M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $2.87M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.16M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $32.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.04M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.70M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.52M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.66M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.66M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | $2.24M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $6.38M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $5.37M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $4.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $781.5K | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $1.88M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($127.3K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($171.0K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $622.5K | Mar 31, 2020 |
| FY2018 | Dec 31, 2016 | ($5.52M) | Apr 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($74.37M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($63.60M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($52.36M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($45.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($39.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($32.74M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($30.27M) | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | ($28.69M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($23.52M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.94M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $174.4K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $140.1K | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $85.4K | Apr 1, 2016 |
| FY2014 | Dec 31, 2013 | $166 | Apr 17, 2015 |
| FY2013 | Dec 31, 2011 | $988 | Apr 15, 2014 |
| FY2012 | Dec 31, 2010 | $70.3K | Apr 1, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $41.6K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $196.6K | Mar 30, 2017 |
| FY2014 | Dec 31, 2014 | $66.0K | Apr 17, 2015 |
| FY2014 | Dec 31, 2013 | $66.0K | Apr 17, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2015 | Dec 31, 2015 | 0 | Apr 1, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Apr 1, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2015 | Dec 31, 2015 | 0 | Apr 1, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Apr 1, 2016 |
| FY2014 | Dec 31, 2013 | (1) | Apr 17, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.45M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 8.92M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 7.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 7.16M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 4.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 3.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 1.98M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 1.51M | Mar 31, 2020 |
| FY2018 | Dec 31, 2017 | 20.65M | Apr 15, 2019 |
| FY2018 | Nov 24, 2017 | 18.76M | Apr 15, 2019 |